Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study ( PIONEER REAL Canada)
Open Access
- 11 March 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (5) , 1799-1807
Abstract
Aim: PIONEER REAL Canada examined real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes. Materials and Methods: This was a 34‐ to 44‐week, multicentre, prospective, open‐label, non‐interventional study in adults who were treatment‐naive to injectable glucose‐lowering medication and initiated oral semaglutide in routine clinical practice. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to the end of the study (EoS). Secondary endpoints assessed at EoS were change from baseline in body weight (BW); the proportion of participants reaching HbA1c levels p < .0001) and −7.17% (−8.24, −6.11; p < .0001), respectively. At EoS, 53.7% of participants had HbA1c levels p < .0001). At EoS, 75.3% of participants remained on oral semaglutide (55.5% received oral semaglutide 14 mg). No new safety signals were identified for oral semaglutide. Conclusions: In PIONEER REAL Canada, participants treated with oral semaglutide in routine clinical practice experienced clinically relevant reductions in HbA1c and BW and increased treatment satisfaction.Keywords
Funding Information
- Novo Nordisk Pharma
This publication has 14 references indexed in Scilit:
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022
- A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetesReviews in Endocrine and Metabolic Disorders, 2022
- Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice ExperimentAdvances in Therapy, 2022
- Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE studyDiabetes, Obesity and Metabolism, 2021
- Canadian Real‐World Outcomes of Omnipod Initiation in People with Type 1 Diabetes (COPPER study): Evidence from the LMC Diabetes RegistryDiabetic Medicine, 2020
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 UpdateCanadian Journal of Diabetes, 2020
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trialThe Lancet Diabetes & Endocrinology, 2019
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trialThe Lancet, 2019
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trialThe Lancet Diabetes & Endocrinology, 2019
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With SulfonylureaJAMA, 2019